California Public Employees Retirement System acquired a new stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) during the first quarter, according to its most recent disclosure with the SEC. The firm acquired 5,100 shares of the company’s stock, valued at approximately $231,000.

A number of other institutional investors have also recently modified their holdings of AERI. Quantbot Technologies LP purchased a new position in shares of Aerie Pharmaceuticals during the first quarter valued at about $107,000. Ameritas Investment Partners Inc. purchased a new position in shares of Aerie Pharmaceuticals during the first quarter valued at about $108,000. Karp Capital Management Corp purchased a new position in shares of Aerie Pharmaceuticals during the first quarter valued at about $213,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Aerie Pharmaceuticals during the first quarter valued at about $259,000. Finally, First Mercantile Trust Co. boosted its position in shares of Aerie Pharmaceuticals by 29.9% in the first quarter. First Mercantile Trust Co. now owns 7,031 shares of the company’s stock valued at $319,000 after buying an additional 1,620 shares in the last quarter. 94.64% of the stock is owned by hedge funds and other institutional investors.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) traded up 3.17% during trading on Thursday, hitting $56.90. The stock had a trading volume of 185,143 shares. The firm’s 50-day moving average price is $54.13 and its 200-day moving average price is $48.67. The stock’s market cap is $2.07 billion. Aerie Pharmaceuticals, Inc. has a 1-year low of $18.52 and a 1-year high of $59.50.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.02. On average, equities research analysts predict that Aerie Pharmaceuticals, Inc. will post ($2.56) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “California Public Employees Retirement System Takes Position in Aerie Pharmaceuticals, Inc. (AERI)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/31/california-public-employees-retirement-system-takes-position-in-aerie-pharmaceuticals-inc-aeri.html.

Several brokerages recently issued reports on AERI. Cowen and Company set a $100.00 price objective on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, May 26th. Canaccord Genuity set a $65.00 price objective on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 16th. Needham & Company LLC lifted their price objective on Aerie Pharmaceuticals from $58.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, May 25th. BidaskClub cut Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, June 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $62.00 price objective (up from $56.00) on shares of Aerie Pharmaceuticals in a report on Thursday, July 20th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $66.08.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.